National Institute on Aging; Notice of Closed Meeting, 81556 [2015-32773]
Download as PDF
81556
Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: A Novel FullyHuman Anti-CD30 Chimeric Antigen
Receptor for Treatment of CD30+
Lymphoma.
Description of Technology: Chimeric
antigen receptors (CARs) are hybrid
proteins that consist of two major
components: A targeting domain and a
signaling domain. The targeting domain
allows T cells which express the CAR to
selectively recognize and bind to
diseased cells that express a particular
protein. Once the diseased cell is bound
by the targeting domain of the CAR, the
signaling domain of the CAR activates
the T cell, thereby allowing it to kill the
diseased cell. This is a promising new
therapeutic approach known as
adoptive cell therapy (ACT).
Researchers at the National Cancer
Institute’s Experimental Transplantation
and Immunology Branch developed a
CAR that recognizes human tumor
necrosis factor receptor superfamily
member 8 (TNFRSF8, also known as
CD30). The expression of CD30 is
deregulated in a variety of human
cancers, including many lymphomas.
By creating a CAR that recognizes CD30,
it may be possible to treat these cancers
using adoptive cell therapy.
Potential Commercial Applications
—Treatment of human cancers
associated with expression of CD30 or
variants thereof
—Specific cancers include: NonHodgkins Lymphomas, Hodgkin’s
Lymphomas, several solid malignancies
mstockstill on DSK4VPTVN1PROD with NOTICES
Value Proposition
—Human components are less likely
to cause adverse or neutralizing immune
response in patients
—Targeted therapies decrease nonspecific killing of healthy cells and
tissues, resulting in fewer off-target sideeffects and healthier patients
Development Stage
In vivo/Lead Validation.
Inventor(s)
Jim N. Kochenderfer, M.D. (NCI).
VerDate Sep<11>2014
17:59 Dec 29, 2015
Jkt 238001
Intellectual Property
HHS Reference No. E–001–2016/0–US–
01
US Provisional Application 62/241,896
(HHS Reference No. E–001–2016/0–
US–01) filed October 15, 2015 entitled
‘‘A Novel Fully-Human Anti-CD30
Chimeric Antigen Receptor for
Treatment of CD30+ Lymphoma’’
Licensing Opportunity: Researchers at
the NCI seek licensees for a chimeric
antigen receptor (CAR) that recognizes
human tumor necrosis factor receptor
superfamily member 8 (TNFRSF8, also
known as CD30) for use as a cancer
therapeutic.
Contact Information
Requests for copies of the patent
application or inquiries about licensing
and/or research collaboration and codevelopment opportunities should be
sent to John D. Hewes. Ph.D., email:
john.hewes@nih.gov.
Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2015–32879 Filed 12–29–15; 8:45 am]
Institutes of Health, 7201 Wisconsin Avenue,
Suite 2c212, Bethesda, MD 20892, 301–402–
7705, JOHNSONJ9@NIA.NIH.GOV.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 23, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32773 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0014]
Agency Information Collection
Activities: Affidavit of Support, Form
I–134; Extension, Without Change, of a
Currently Approved Collection
U.S. Citizenship and
Immigration Services, Department of
Homeland Security.
ACTION: 60-day notice.
AGENCY:
BILLING CODE 4140–01–P
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration (USCIS) invites the general
public and other Federal agencies to
comment upon this proposed extension
of a currently approved collection of
information. In accordance with the
Paperwork Reduction Act (PRA) of
1995, the information collection notice
is published in the Federal Register to
obtain comments regarding the nature of
the information collection, the
categories of respondents, the estimated
burden (i.e. the time, effort, and
resources used by the respondents to
respond), the estimated cost to the
respondent, and the actual information
collection instruments.
DATES: Comments are encouraged and
will be accepted for 60 days until
February 29, 2016.
ADDRESSES: All submissions received
must include the OMB Control Number
1615–0014 in the subject box, the
agency name and Docket ID USCIS–
2006–0072. To avoid duplicate
submissions, please use only one of the
following methods to submit comments:
(1) Online. Submit comments via the
Federal eRulemaking Portal Web site at
https://www.regulations.gov under
e-Docket ID number USCIS–2006–0072;
(2) Email. Submit comments to
USCISFRComment@uscis.dhs.gov;
(3) Mail. Submit written comments to
DHS, USCIS, Office of Policy and
Strategy, Chief, Regulatory Coordination
SUMMARY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Alzheimer’s
Center.
Date: February 4, 2016.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
North Bethesda, MD 20852.
Contact Person: Jeannette L. Johnson,
Ph.D., National Institutes on Aging, National
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)]
[Notices]
[Page 81556]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32773]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Alzheimer's Center.
Date: February 4, 2016.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, North Bethesda, MD 20852.
Contact Person: Jeannette L. Johnson, Ph.D., National Institutes
on Aging, National Institutes of Health, 7201 Wisconsin Avenue,
Suite 2c212, Bethesda, MD 20892, 301-402-7705,
JOHNSONJ9@NIA.NIH.GOV.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: December 23, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-32773 Filed 12-29-15; 8:45 am]
BILLING CODE 4140-01-P